

CAPLIN POINT LABORATORIES LIMITED

Registered Office: 3rd Floor, "Ashvich Towers", No.3, Developed Plots Industrial Estates, Perungudi, Chennai 600 096

CIN - L24231TN1990PLC019053, Phone Nos.044-28156653,28156905, Fax No.044-28154952, Website - www.caplinpoint.net, email ID-info@caplinpoint.net

UNAUDITED (CONSOLIDATED) FINANCIAL RESULTS FOR THE THREE MONTHS ENDED 30th JUNE 2020

Prepared in compliance with the Indian Accounting Standards (Ind - AS)

Particulars	Three Months Ended			Financial Year Ended
	30.06.2020	31.03.2020	30.06.2019	31.03.2020
	(1)	(2)	(3)	(4)
	(Unaudited)	(Audited)	(Unaudited)	(Audited)
	INR in Crs			
Income:				
I Revenue from operations	240.08	215.23	192.55	863.20
II Other income	6.49	19.63	4.47	41.33
III Total Income (I+II)	246.57	234.86	197.02	904.53
IV Expenses:				
a. Cost of materials consumed	21.18	23.81	22.46	108.12
b. Purchase of traded goods	23.63	209.39	121.14	500.14
c. Changes in inventories of finished goods, stock in trade and work in progress	63.99	(121.77)	(58.42)	(195.10)
d. Employee benefit expenses	25.87	18.53	15.59	67.76
e. Finance cost	0.51	0.17	0.01	0.32
f. Depreciation & Amortisation Expenses	8.96	8.40	7.39	31.62
g. Other Expenses	33.81	31.46	24.40	122.21
h. Total Expenses	177.95	169.99	132.57	635.07
V Profit before exceptional items and Tax (III-IV)	68.62	64.87	64.45	269.46
VI Exceptional items	-	-	-	-
VII Profit Before Tax (V-VI)	68.62	64.87	64.45	269.46
VIII Tax Expenses				
(1) Current Tax	17.79	18.17	14.50	61.84
(2) Deferred Tax (Refer Note 6)	(3.72)	(2.16)	(0.11)	(7.46)
Total Tax Expenses	14.07	16.01	14.39	54.38
IX Net Profit for the period (VII - VIII)	54.55	48.86	50.06	215.08
X Other Comprehensive Income - Net of Tax				
A. Items that will not be re-classified to profit or loss				
i) Remeasurements of Defined Benefit Plan	-	(0.30)	(0.30)	(0.70)
ii) Surplus on acquisition of subsidiary	-	1.99	-	1.99
B. Items that will be re-classified to profit or loss				
i) Exchange difference in translating the financial statements of foreign operations	(0.01)	9.63	(0.07)	15.39
XI Total Comprehensive Income For The Period (IX + X)	54.54	60.18	49.69	231.76
XII Profit attributable to:				
Owners of the Company	54.54	48.89	50.23	215.01
Non- controlling interests	0.02	(0.03)	(0.17)	0.08
	54.56	48.86	50.06	215.09
XIII Total Comprehensive Income For The Period attributable to				
Owners of the Company	54.53	60.21	49.86	231.68
Non- controlling interests	0.02	(0.03)	(0.17)	0.08
	54.55	60.18	49.69	231.76
XIV Paid up Equity Share Capital (Face value of share of Rs 2/- each)	15.13	15.13	15.13	15.13
XV Reserves excluding Revaluation Reserves as per Balance Sheet of previous accounting year	-	-	-	858.2
XVI Earnings Per Share (EPS) (Not annualised) based on face value Rs 2/- per Equity share				
(a) Basic (in Rupees)	7.21	6.46	6.64	28.42
(b) Diluted (in Rupees)	7.15	6.41	6.60	28.20



Signature

Notes :

- 1) The above consolidated financial results for the quarter ended 30th June 2020 have been reviewed and recommended by the Audit Committee and have been approved by the Board of Directors of the Company at their respective meetings held on 10th August, 2020
- 2) The consolidated financial results of the Company has been prepared in accordance with the Indian Accounting Standards prescribed under Section 133 of the Companies Act, 2013 (" the Act") read with relevant rules issued thereunder ("Ind AS") and other accounting principles generally accepted in India and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- 3) The Company operates exclusively in one reportable business segment i.e., "Pharmaceuticals formulations". There is no exceptional and/or extra ordinary item.
- 4) During the Quarter ended 30th June, 2020 the Company has allotted NIL equity shares of Rs. 2/- each under the Employees Stock Option Scheme 2015 as compared to 12,500 equity shares for the corresponding periods of last year.
- 5) Revenue from operations is disclosed net of Goods & Service Tax/ Value Added Tax as applicable
- 6) The Group has taken into consideration the possible effects that may result from the pandemic relating to COVID-19 in the preparation of the financial statements, including but not limited to its assesment of the carrying amounts of receivables, inventories and investments. The Company has been able to effectively manage the operations till now with appropriate safety precautions without any significant impact of COVID 19. The actual impact of COVID-19 in coming quarters may be different from that of this quarter, depending on how the situation evolves globally. The company will continue to closely monitor any material changes to future economic conditions to ensure business continuity.
- 7) The Statutory Auditors of the Company have carried out limited review of the above Consolidated Financial Results pursuant to regulation 33 of the SEBI (Listing obligations & Disclosure Requirements) Regulations,2015. An unqualified opinion has been issued by them thereon.
- 8) As the Parent Company's wholly owned subsidiary Caplin Point Far East Limited, Hong Kong had acquired subsidiaries in Nicaragua (in Q1), Honduras (in Q2), Ecuador and Guatemala (in Q4) in FY 19-20, the current quarter results are not comparable with the previous periods.
- 9) The figures for the quarters ended 31st March, 2020 are the balancing numbers between audited figures in respect of the full financial years and the published unaudited year to date figures upto the end of the third quarter of the relevant financial year, which was subject to limited review
- 10) Prior year / period figures are regrouped / rearranged wherever necessary.

For and on behalf of the Board



Dr. Sridhar Ganesan
Managing Director

Place: Chennai

Date: 10th August, 2020



CAPLIN POINT LABORATORIES LIMITED					
Registered Office: 3rd Floor, "Ashvich Towers", No.3, Developed Plots Industrial Estates, Perungudi, Chennai 600 096					
CIN - L24231TN1990PLC019053, Phone Nos.044-28156653,28156905, Fax No.044-28154952, Website - www.caplinpoint.net, email ID- info@caplinpoint.net					
UNAUDITED (STANDALONE) FINANCIAL RESULTS FOR THE THREE MONTHS ENDED 30th JUNE 2020					
Prepared in compliance with the Indian Accounting Standards (Ind - AS)					
	Particulars	Three Months Ended			Financial Year Ended
		30.06.2020 (1) (Unaudited)	31.03.2020 (2) (Audited)	30.06.2019 (3) (Unaudited)	31.03.2020 (4) (Audited)
INR In Crs					
	Income:				
I	Revenue from operations	119.73	100.12	140.27	527.83
II	Other income (Refer Note 4)	4.05	33.01	19.94	65.97
III	Total Income (I+II)	123.78	133.13	160.21	593.80
	Expenses:				
IV	a. Cost of materials consumed	18.83	20.39	20.88	95.73
	b. Purchase of traded goods	26.35	29.35	38.56	143.18
	c. Changes in inventories of finished goods, stock in trade and work in progress	3.58	(3.36)	2.39	(0.74)
	d. Employee benefit expenses	6.22	4.76	6.70	25.00
	e. Finance cost	0.05	0.05	0.01	0.18
	f. Depreciation & Amortisation Expenses	5.43	5.68	4.36	19.65
	g. Other Expenses	7.30	10.46	13.28	57.66
	h. Total Expenses	67.76	67.33	86.18	340.66
V	Profit before exceptional items and Tax (III-IV)	56.02	65.80	74.03	253.14
VI	Exceptional items		-	-	-
VII	Profit Before Tax (V-VI)	56.02	65.80	74.03	253.14
VIII	Tax Expenses				
	(1) Current Tax	14.48	15.68	13.20	55.89
	(2) Deferred Tax	(0.48)	(0.01)	0.73	(0.40)
	Total Tax Expenses	14.00	15.67	13.93	55.49
IX	Net Profit for the period (VII-VIII)	42.02	50.13	60.10	197.65
X	Other Comprehensive Income/ (Loss) - Net of Tax				
	A. Items that will not be re-classified to profit or loss				
	i) Remeasurements of Defined Benefit Plan	-	(0.09)	(0.13)	(0.33)
XI	Total Comprehensive Income For The Period (IX+X)	42.02	50.04	59.97	197.31
XII	Paid up Equity Share Capital (Face value of shares of Rs 2/- each)	15.13	15.13	15.13	15.13
XIII	Reserves excluding Revaluation Reserves as per Balance Sheet of previous accounting year	-	-	-	584.78
XIV	Earnings Per Share (EPS) based on face value Rs 2/- per Equity share				
	(a) Basic (in Rupees)	5.55	6.63	7.95	26.13
	(b) Diluted (in Rupees)	5.52	6.58	7.90	25.95
		(Not Annualised)	(Not Annualised)	(Not Annualised)	Annualised



Signature

Notes :

- 1) The above standalone financial results for the quarter ended 30th June 2020 have been reviewed and recommended by the Audit Committee and have been approved by the Board of Directors of the Company at their respective meetings held on 10th August, 2020
- 2) The standalone financial results of the Company have been prepared in accordance with the Indian Accounting Standards prescribed under Section 133 of the Companies Act, 2013 (" the Act") read with relevant rules issued thereunder ("Ind AS") and other accounting principles generally accepted in India and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirments) Regulations, 2015.
- 3) The Company operates exclusively in one reportable business segment i.e., "Pharmaceuticals formulations". There is no exceptional and/or extra ordinary item.
- 4) Other Income and PBT for the quarter ended 30th June 2020 includes Dividend of Rs. NIL as against Rs.17.53 Cr and Rs. 15.37 Cr of Dividend Income in quarter ended 30th June' 2019 and 31st March' 2020 respectively , received from our wholly owned subsidiary Caplin Point Far East Limited, Hong Kong.
- 5) Revenue from operations is disclosed net of Goods and Service Tax

The Company has taken into consideration the possible effects that may result from the pandemic relating to COVID-19 in the preparation of the financial statements, including but not limited to its assesement of the carrying amounts of receivables, inventories and investments. The Company has been able to effectively manage the operations till now with appropriate safety precautions without any significant impact of COVID 19. The actual impact of COVID-19 in coming quarters may be different from that of this quarter, depending on how the situation evolves globally. The company will continue to closely monitor any material changes to future economic conditions to ensure business continuity.

- 6) The Statutory Auditors of the Company have carried out limited review of the above Standalone Financial Results pursuant to regulation 33 of the SEBI (Listing obligations & Disclosure Requirements) Regulations,2015. An unqualified opinion has been issued by them thereon.

- 7) During the Quarter ended 30th June, 2020 the Company has allotted NIL equity shares of Rs. 2/- each under the Employees Stock Option Scheme 2015 as compared to 12,500 equity shares for the corresponding periods of last year.

- 8) The figures for the quarters ended 31st March, 2020 are the balancing numbers between audited figures in respect of the full financial years and the published unaudited year to date figures upto the end of the third quarter of the relevant financial year, which was subject to limited review

- 9) Prior year / period figures are regrouped / rearranged wherever necessary.

Place: Chennai
Date: 10th August, 2020



For and on behalf of the Board

Dr. Sridhar Ganesan
Managing Director